Use of bisphosphonates for the treatment of osteogenesis imperfecta

Abstract

This procedure consists in the first stage, of the administration of enough quantity of bisphosphonate preparation during the necessary period of time to acquire a degree of volumetric mineral density of the cortical tissue of application, within the normal range (average±1 DS). Then the administration of the bisphosphonate preparation is interrupted in order to enable the development of the sectional momentum of inertia. The length of the second stage can be determined by means of a tomography. That is to say, that the periods of administration or non-administration of the mineralizing agent are defined or controlled by precise osteologic variables and therefore are not fixed. If during the second stage the cortical mineral density drops by 6-10% of the maximum value previously obtained, administration of bishphosphonate preparation should be resumed until the corresponding maximum adjusted value is reached again. The proposed procedure of a period with bisphosphonate followed by another period without the bisphosphonate agent improves fracture resistance, provided that the length of both periods is controlled by defined osteologic variables.

1 - 31 . (Canceled)  
     
     
         32 . A kit comprising a plurality of bisphosphonate dosage forms for the treatment of Osteogenesis imperfecta.  
     
     
         33 . A kit according to  claim 32 , further comprising a package insert specifying the use.  
     
     
         34 . A process applicable to medical preparations of bisphosphonates and their formulation for the treatment of osteogenesis imperfecta in a patient comprising: 
 administering a sufficient amount of the preparation of bisphosphonates to the patient until a volumetric mineral density of the cortical tissue is within a normal range (means±1 DS) of the volumetric mineral density of a person of the same age of the patient;    interrupting the administration of the preparation of bisphosphonate during the time in which the volumetric mineral density does not drop lower than 5-10% from the normal range (means±1 DS) of the volumetric mineral density of a person of the same age of the patient;    resuming the administration of the bisphosphonates when the volumetric mineral density falls by 5-10% of the normal range (means±1 DS) of the volumetric mineral density of a person of the same age of the patient, until the normal range (means±1 DS) of the volumetric mineral density of the person of the same age of the patient is reached again; and so forth.    
     
     
         35 . The process according to  claim 34 , wherein the preparation contains at least two bisphosphonate and some of the synergic combinations formed by the pharmaceutically acceptable calcium salts, pharmaceutically acceptable fluor salts, vitamin D, PTH, fractions of PTH or other hormones.  
     
     
         36 . The process according to  claim 34 , wherein the administration of bisphosphonate preparations in gastro-resistant formulations is administered orally.  
     
     
         37 . The process according to per claims  34 , further comprising administering bisphosphonates at 25 to 300 mg daily doses.  
     
     
         38 . The process according to  claim 34 , wherein the bisphosphonate is disodium pamidronate.  
     
     
         39 . The process according to  claim 34 , wherein the bisphosphonate is an injectable preparation, wherein the doses of bisphosphonates are from 5-60 mg for each administration at one-week to six-month intervals.  
     
     
         40 . The process according to  claim 34 , wherein the preparation containing bisphosphonates is comprised in a pharmaceutical preparation chosen from tablets, capsules, solid forms, liquid soluble, suspension forms, gels, and soft capsules.  
     
     
         41 . The process according to  claim 34 , wherein the bisphosphonate is olpadronate.  
     
     
         42 . The process according to  claim 34 , wherein the preparation is obtained in a box designed with combined presentation packaging.  
     
     
         43 . The process according to  claim 34 , wherein the preparation is obtained in a box designed with conjoint presentation packaging.